Astrana Health (NASDAQ:ASTH) Shares Up 3.9% – What’s Next?

Astrana Health, Inc. (NASDAQ:ASTH) shot up 3.9% on Tuesday . The company traded as high as $31.66 and last traded at $31.81. 130,682 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 249,187 shares. The stock had previously closed at $30.60.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ASTH. Robert W. Baird decreased their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Truist Financial decreased their target price on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research note on Tuesday. Stifel Nicolaus reduced their price objective on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Finally, Bank of America reduced their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Price Performance

The company has a market capitalization of $1.81 billion, a PE ratio of 24.73, a PEG ratio of 1.37 and a beta of 1.30. The firm has a fifty day moving average of $33.95 and a two-hundred day moving average of $42.95. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). The company had revenue of $665.21 million for the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Research analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Several institutional investors have recently bought and sold shares of ASTH. State Street Corp purchased a new stake in Astrana Health during the 3rd quarter valued at about $91,966,000. Geode Capital Management LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $58,995,000. FMR LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $48,413,000. Loomis Sayles & Co. L P purchased a new stake in Astrana Health in the 3rd quarter worth approximately $30,251,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Astrana Health in the 3rd quarter worth approximately $25,945,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.